Mirati Therapeutics and Array BioPharma have collaborated to identify an irreversible small molecule covalent inhibitor of KRASG12C, adagrasib (MRTX-849) (2).57 Adagrasib binds covalently to Cys12 of KRASG12C and extends to allosteric pocket S-II P, thereby locking KRAS proteins into inactive conformations and inhibiting RAS/MAPK kinase signaling.58 At the maximum effective dose of 100 mg kg−1 d−1, adagrasib demonstrated dose-dependent antitumor effects against different tumor models. This evidence concerns the gene KRAS and neoplasm.